{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T09:57:49Z","timestamp":1773655069521,"version":"3.50.1"},"reference-count":0,"publisher":"Australian Centre for Disease Control","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Commun Dis Intell (2018)"],"abstract":"<jats:p>In Australia, both probable and laboratory-confirmed cases of invasive meningococcal disease (IMD) are reported to the National Notifiable Diseases Surveillance System (NNDSS). Compared to 2021, the number of IMD notifications in 2022 increased by 81% to 127, alongside the easing of COVID-19 containment measures. Laboratory confirmation occurred in 95% of these cases, with 51% (62\/121) diagnosed by bacterial culture and 49% (59\/121) by nucleic acid amplification testing. The serogroup was determined for 97% of laboratory-confirmed cases (117\/121): serogroup B (MenB) accounted for 83% of infections (100\/121); MenW for 4% (5\/121); MenY for 10% (12\/121); no infections were attributed to MenC disease. Fine typing was available on 67% of the cases for which the serogroup was determined (78\/117). In MenB isolates, 27 porA types were detected, the most prevalent of which were P1.7-2,4 (18%;11\/62), P1.22,14 (15%; 9\/62), P1.18-1,34 (10%; 6\/62) and P1.7,16-26 (10%; 6\/62). All five MenW infections identified as porA type P1.5,2 with different MLST sequence types (ST): 11, 574, 1287, 12351, 13135 all belonging to clonal complex 11, the hypervirulent strain reported in outbreaks in Australia and overseas. In MenY, the predominant porA type was P1.5-1,10-1 (73%; 8\/11), ST 1655 and from clonal complex 23.  Children less than 5 years of age and people aged 15\u201319 years were overrepresented with IMD notifications, accounting for 22% (27\/121) and 23% (28\/121) of laboratory-confirmed cases respectively. Fifteen percent of laboratory-confirmed notifications (18\/121) were in persons aged 45\u201364 years. MenB infections were detected in all age groups but predominated in persons aged 15\u201319 years (93% of IMD in this age group; 26\/28) and comprised 89% (24\/27) of infections in children aged less than 5 years. MenW infections were markedly reduced in 2022, accounting for two IMD detections in children 1\u20134 years (2\/16) and sporadic detections in other older age groups. MenY infections were largely detected in adults aged 45\u201364 years, accounting for 28% of IMD in this age group (5\/18).  All 62 cultured IMD isolates had antimicrobial susceptibility testing performed. Minimum inhibitory concentration (MIC) values were categorised using Clinical Laboratory Standards Institute (CLSI) interpretative criteria: 5% (3\/62) were defined as penicillin resistant (MIC value \u2265 0.5 mg\/L); 71% (44\/62) had intermediate susceptibility to penicillin (MIC values 0.125 and 0.25 mg\/L) and 24% (15\/62) were susceptible to penicillin. All isolates were susceptible to ceftriaxone, ciprofloxacin and rifampicin.<\/jats:p>","DOI":"10.33321\/cdi.2023.47.44","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T21:06:26Z","timestamp":1692824786000},"source":"Crossref","is-referenced-by-count":3,"title":["Australian Meningococcal Surveillance Programme Annual Report, 2022"],"prefix":"10.33321","volume":"47","author":[{"given":"Monica M","family":"Lahra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CR Robert","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastiaan J","family":"van Hal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany R","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18788","published-online":{"date-parts":[[2023,8,24]]},"container-title":["Communicable Diseases Intelligence"],"original-title":[],"link":[{"URL":"https:\/\/www1.health.gov.au\/internet\/main\/publishing.nsf\/Content\/8FA6078276359430CA257BF0001A4C42\/$File\/australian_meningococcal_surveillance_programme_annual_report_2022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T18:43:32Z","timestamp":1749581012000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojs.cdi.cdc.gov.au\/index.php\/cdi\/article\/view\/41"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":0,"URL":"https:\/\/doi.org\/10.33321\/cdi.2023.47.44","relation":{},"ISSN":["2209-6051"],"issn-type":[{"value":"2209-6051","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,24]]}}}